A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients th...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: You, Byung Chul, Kim, Young Seok, Kim, Hun il, Kim, Se Hun, Park, Seung Sik, Seo, Yu Ri, Kim, Sang Gyune, Lee, Se Whan, Kim, Hong Soo, Jeong, Soung Won, Jang, Jae Young, Kim, Boo Sung
Format: Artigo
Jezik:Inglês
Izdano: The Korean Association for the Study of the Liver 2012
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3467430/
https://ncbi.nlm.nih.gov/pubmed/23091807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2012.18.3.272
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki